Search

Your search keyword '"Mozzillo, E"' showing total 7 results
Start Over Author "Mozzillo, E" Journal diabetes care
7 results on '"Mozzillo, E"'

4. Low prevalence of HNF1A mutations after molecular screening of multiple MODY genes in 58 Italian families recruited in the pediatric or adult diabetes clinic from a single Italian hospital

Author

Maurizio, Delvecchio, Ornella, Ludovico, Claudia, Menzaghi, Rosa, Di Paola, Leopoldo, Zelante, Antonella, Marucci, Valeria, Grasso, Vincenzo, Trischitta, Massimo, Carella, Fabrizio, Barbetti, Francesco, Gallo, Maria Susanna, Coccioli, Clara, Zecchino, Maria Felicia, Faienza, Giuliana, Cardinale, Adriana, Franzese, Enza, Mozzillo, Dario, Iafusco, Angela, Zanfardino, Delvecchio, M, Ludovico, O, Menzaghi, C, Di Paola, R, Zelante, L, Marucci, A, Grasso, V, Trischitta, V, Carella, M, Barbetti, F, Gallo, F, Coccioli, M, Zecchino, C, Faienza, Mf, Cardinale, G, Franzese, A, Mozzillo, E, Iafusco, Dario, Zanfardino, A., Delvecchio, M., Ludovico, O., Menzaghi, C., Di Paola, R., Zelante, L., Marucci, A., Grasso, V., Trischitta, V., Carella, M., Barbetti, F., Gallo, F., Coccioli, Ms., Zecchino, C., Faienza, Mf., Cardinale, G., Franzese, A., Mozzillo, E., and Iafusco, D.

Subjects
Adult, Pediatrics, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Basic Helix-Loop-Helix Transcription Factor, DNA Mutational Analysis, Polymorphism, Single Nucleotide, Settore MED/13 - Endocrinologia, DNA Mutational Analysi, Hospital, Gene Frequency, Polymorphism (computer science), Diabetes mellitus, Glucokinase, Internal Medicine, medicine, Basic Helix-Loop-Helix Transcription Factors, Prevalence, Humans, Hepatocyte Nuclear Factor 1-alpha, Child, Gene, Allele frequency, Hepatocyte Nuclear Factor 1-beta, Advanced and Specialized Nursing, Homeodomain Proteins, Type 1 diabetes, Molecular screening, business.industry, Medicine (all), Homeodomain Protein, medicine.disease, Hospitals, HNF1A, Pedigree, Diabetes Mellitus, Type 2, Hepatocyte Nuclear Factor 4, Italy, Trans-Activator, Mutation, Trans-Activators, business, Human
Abstract

Maturity-onset diabetes of the young (MODY; MIM# 606391) is a genetically and clinically heterogeneous form of diabetes, accounting for 1–2% of all diabetes cases (1). MODY is characterized by mild hyperglycemia or overt diabetes usually detected in three consecutive generations, with onset before the age of 25 years and absence of type 1 diabetes autoantibodies. Among the thirteen MODY genes identified, two subtypes, GCK -MODY and HNF1A -MODY, account for most of cases (1). The prevalence of GCK -MODY has been reported higher in Southern Europe (2), while HNF1A -MODY is the most common MODY subtype in Northern Europe (3). This difference might be attributable to the clinical setting in which genetic screening is performed, especially when pediatric and adult diabetes clinics are distinct entities. We addressed this issue by investigating MODY patients identified in the pediatric or in the adult diabetes clinics of the same research-based …

Published
2014

5. Glucose Derangements in Very Young Children With Cystic Fibrosis and Pancreatic Insufficiency

Author

Valentina Fattorusso, Mariateresa Falco, Rosa Nugnes, Angela Sepe, Valeria Raia, Adriana Franzese, Enza Mozzillo, Giuliana Valerio, Fabiola De Gregorio, Mozzillo, E, Raia, Valeria, Fattorusso, V, Falco, M, Sepe, A, De Gregorio, F, Nugnes, R, Valerio, G, and Franzese, Adriana

Subjects
Blood Glucose, Male, medicine.medical_specialty, Pediatrics, Cystic Fibrosis, Endocrinology, Diabetes and Metabolism, Cystic fibrosis, children, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Endocrine system, Humans, In patient, Online Letters: Observations, Prediabetes, Exocrine pancreatic insufficiency, Child, cystic fibrosi, Advanced and Specialized Nursing, Glucose tolerance test, medicine.diagnostic_test, diabetes, business.industry, Glucose Tolerance Test, medicine.disease, Comorbidity, Endocrinology, Glucose, Child, Preschool, Exocrine Pancreatic Insufficiency, Female, business
Abstract

Cystic fibrosis–related diabetes (CFRD) is considered the most common comorbidity in patients affected by cystic fibrosis (CF), with a prevalence increasing with age (1). Recently, more attention has been turned to other less severe glucose metabolism derangements (GMD), since prediabetes may be related to increased morbidity (1), and early treatment may improve the clinical course in patients with CF (2). According to recent guidelines released by the Cystic Fibrosis Foundation, the American Diabetes Association, and the Pediatric Endocrine Society, the oral glucose tolerance test (OGTT) is recommended yearly in patients with CF over 10 years of age (3). Some authors recommend annual OGTT after the age of 6 years in CF patients with pancreatic insufficiency (4). In …

Published
2012

6. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study.

Author

Passanisi S, Salzano G, Bombaci B, Minuto N, Bassi M, Bonfanti R, Scialabba F, Mozzillo E, Di Candia F, Monti S, Graziani V, Maffeis C, Piona CA, Arnaldi C, Tosini D, Felappi B, Roppolo R, Zanfardino A, Delvecchio M, Lo Presti D, Calzi E, Ripoli C, Franceschi R, Reinstadler P, Rabbone I, Maltoni G, Alibrandi A, Zucchini S, Marigliano M, and Lombardo F

Subjects
Humans, Adolescent, Child, Male, Female, Hypoglycemic Agents therapeutic use, Hypoglycemic Agents administration & dosage, Longitudinal Studies, Blood Glucose Self-Monitoring methods, Glycated Hemoglobin metabolism, Glycated Hemoglobin analysis, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 1 blood, Insulin Infusion Systems, Blood Glucose analysis, Blood Glucose metabolism, Insulin administration & dosage, Insulin therapeutic use
Abstract

Objective: To investigate glucose metrics and identify potential predictors of the achievement of glycemic outcomes in children and adolescents during their first 12 months of MiniMed 780G use., Research Design and Methods: This multicenter, longitudinal, real-world study recruited 368 children and adolescents with type 1 diabetes (T1D) starting SmartGuard technology between June 2020 and June 2022. Ambulatory glucose profile data were collected during a 15-day run-in period (baseline), 2 weeks after automatic mode activation, and every 3 months. The influence of covariates on glycemic outcomes after 1 year of MiniMed 780G use was assessed., Results: After 15 days of automatic mode use, all glucose metrics improved compared with baseline (P < 0.001), except for time below range (P = 0.113) and coefficient of variation (P = 0.330). After 1 year, time in range (TIR) remained significantly higher than at baseline (75.3% vs. 62.8%, P < 0.001). The mean glycated hemoglobin (HbA1c) over the study duration was lower than the previous year (6.9 ± 0.6% vs. 7.4 ± 0.9%, P < 0.001). Time spent in tight range (70-140 mg/dL) was 51.1%, and the glycemia risk index was 27.6. Higher TIR levels were associated with a reduced number of automatic correction boluses (P < 0.001), fewer SmartGuard exits (P = 0.021), and longer time in automatic mode (P = 0.030). Individuals with baseline HbA1c >8% showed more relevant improvement in TIR levels (from 54.3% to 72.3%)., Conclusions: Our study highlights the sustained effectiveness of MiniMed 780G among youth with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology., (© 2024 by the American Diabetes Association.)

Published
2024
Full Text
View/download PDF

7. Low prevalence of HNF1A mutations after molecular screening of multiple MODY genes in 58 Italian families recruited in the pediatric or adult diabetes clinic from a single Italian hospital.

Author

Delvecchio M, Ludovico O, Menzaghi C, Di Paola R, Zelante L, Marucci A, Grasso V, Trischitta V, Carella M, Barbetti F, Gallo F, Coccioli MS, Zecchino C, Faienza MF, Cardinale G, Franzese A, Mozzillo E, Iafusco D, and Zanfardino A

Subjects
Adult, Basic Helix-Loop-Helix Transcription Factors genetics, Child, DNA Mutational Analysis, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 epidemiology, Gene Frequency, Glucokinase genetics, Hepatocyte Nuclear Factor 1-beta genetics, Hepatocyte Nuclear Factor 4 genetics, Homeodomain Proteins genetics, Hospitals, Humans, Italy epidemiology, Pedigree, Polymorphism, Single Nucleotide, Prevalence, Trans-Activators genetics, Diabetes Mellitus, Type 2 genetics, Hepatocyte Nuclear Factor 1-alpha genetics, Mutation
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results